Use of Transmucosal Ketamine in Post Stroke Depression

Studies have shown that ketamine is very effective and has a quick onset in the treatment of depression. Most of these studies used intravenous ketamine in an inpatient setting and there are no large trials examining its use in Post Stroke Depression (PSD).

There have been only a few studies that have used other routes of administration (i.e., oral, transmucosal, intranasal, intramuscular) of ketamine which provided symptom relief for depression.

The purpose of this study is to assess the effectiveness and safety of the use of transmucosal ketamine in the treatment of PSD. We hypothesize that fast-acting antidepressant effects can be achieved with tolerable side effects for translation into the general post-stroke population.

To test our hypothesis, the specific aim is to: (1) demonstrate that transmucosal administration of ketamine is feasible within the post-stroke depression population and has tolerable side effects. Exploratory aims will include assessment if ketamine also produces fast-acting antidepressant effects.

Topic Depression
Compound Ketamine
Country United States of America
Visit trial
Status Recruiting
Results Published
Start date 30 November 2020
End date 01 November 2022
Chance of happening 100%
Phase Phase I
Design Open
Type Interventional
Generation First
Participants 21
Sex All
Age 18- 99
Therapy No

Trial Details



NCT Number NCT04876066

Sponsors & Collaborators

Mayo Clinic
This company doesn't have a full profile yet, it is linked to a clinical trial.

Measures Used

Montgomery-Asberg Depression Rating Scale
A ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.